Market Overview

Why Immunovant Could Benefit From The J&J-Momenta Deal

Why Immunovant Could Benefit From The J&J-Momenta Deal

Immunovant Inc (NASDAQ: IMVT) shares were ripping higher Wednesday in a sympathy move.

What Happened: Shares of New York-based Immunovant, which focuses on treatment for autoimmune disorders, gap-opened Wednesday's session higher and were seen trading with notable gains.

This is despite a lack of any company-specific announcement.

The gains can be traced to a deal announced by Johnson & Johnson (NYSE: JNJ) to buy another autoimmune diseases-focused biopharma, Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA).

Momenta's lead drug nipocalimab is anti-FcRn antibody that is currently being developed in clinical programs for multiple autoimmune disorder indications.

Analyst Sees Positive Read-Through For Immunovant: The J&J-Momenta deal validates the anti-FcRn space, SVB Leerink analyst Thomas Smith said in a Wednesday note. 

The deal represents the first significant M&A investment in the class from a large pharma or biotech beyond Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), which had previously completed smaller licensing transactions for ALXN1830 and ABY-039, the analyst said. 

Immunovant's investigational product candidate IMVT-1401 is also an anti-FcRn antibody.

The validation of the substantial FcRn opportunity is likely to drive Immunovant shares higher, Smith said. 

SVB Leerink continues to see Immunovant as well-positioned to capitalize on increasing strategic interest in the class, given IMVT-1401's favorable attributes, which include competitive IgG lowering, a relatively clean safety/tolerability profile vs. the rest of the FcRn class and a subcutaneous injection formulation, the analyst said. 

SVB Leerink reiterated an Outperform rating on Immunovant with a $26 price target. 

IMVT Price Action: Immunovant shares were rallying 11.67% to $30.72 at the time of publication Wednesday. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs

Latest Ratings for IMVT

Oct 2020GuggenheimInitiates Coverage OnBuy
Oct 2020StifelInitiates Coverage OnBuy
Oct 2020Credit SuisseInitiates Coverage OnOutperform

View More Analyst Ratings for IMVT
View the Latest Analyst Ratings


Related Articles (IMVT)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech M&A Price Target Reiteration Analyst Ratings Movers Trading Ideas Best of Benzinga

Latest Ratings

INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at